PRESS RELEASE
FOR IMMEDIATE
RELEASE
May 15, 2018
Contact: CMS Media
Relations
(202) 690-6145 | CMS
Media Inquiries
CMS Unveils Enhanced “Drug
Dashboards” to Increase Transparency on Drug Prices
An
important part of the American Patients First initiative, the Dashboards
provide new information on changes in spending per drug over time
Today,
the Centers for Medicare & Medicaid Services (CMS) released a
redesigned version of the Drug Spending Dashboards. For the first time,
the dashboards include year-over-year information on drug pricing and
highlight which manufactures have been increasing their prices.
“Under
President Trump’s bold leadership, CMS is committed to putting patients
first and increasing transparency,” said CMS Administrator Seema Verma.
“Publishing how much individual drugs cost from one year to the next will
provide much-needed clarity and will empower patients and doctors with
the information they need. As Secretary Azar has repeatedly pointed out,
for years Medicare incentives have actually encouraged higher list prices
for drugs, and this updated and enhanced dashboard is an important step
to bringing transparency and accountability to what has been a largely
hidden process.”
The
dashboards are interactive online tools that allow patients, clinicians,
researchers, and the public to understand trends in drug spending. Data
is reported for both Medicare and Medicaid. The new version of the
dashboard reports the percentage change in spending on drugs per dosage
unit and includes an expanded list of drugs.
Some
of the most commonly used drugs across Medicare Part B, Medicare Part D,
and Medicaid saw double-digit annual increases over the last few
years. A few examples are highlighted in the tables below.
Taking the 15 drugs with the highest total spending in each program, the
drugs listed in the tables saw significant annual increases in spending
per dosage unit from 2012 to 2016. Drugs were included if they
experienced annual increases of at least 5 percent in Part B and at least
10 percent in Part D and Medicaid.
In
2012, Medicare spent 17 percent of its total budget, or $109 billion, on
prescription drugs. Four years later in 2016, spending had
increased to 23 percent, or $174 billion. In 2016, the drugs listed
below accounted for $39 billion in total spending by Medicare and
Medicaid.
Medicare Part B
|
|
Brand Name
|
Generic Name
|
Annual Growth Rate (2012-2016)
|
Average Monthly Spending Per Beneficiary in 2016
|
Manufacturers
|
1
|
Orencia*
|
Abatacept*
|
17.2%
($22 to $41)
|
$2,136
|
BMS Primarycare
|
2
|
Neulasta
|
Pegfilgrastim
|
8.5%
($2,788 to $3,869)
|
$1,195
|
Amgen
|
3
|
Xolair
|
Omalizumab
|
8.0%
($22 to $30)
|
$1,821
|
Genentech, Inc.
|
4
|
Vaccine Influenza Injection Muscle (Fluzone High-Dose)**
|
|
6.9%
($30 to $39)
|
N/A
|
|
5
|
Sandostatin Lar*
|
Octreotide Acetate, mi-Spheres*
|
6.8%
($123 to $160)
|
$3,202
|
Novartis
|
6
|
Prevnar 13
|
Pneumococcal 13-Valent Vaccine
|
6.1%
($132 to $167)
|
N/A
|
Wyeth Pharm
|
7
|
Remicade
|
Infliximab
|
6.0%
($63 to $80)
|
$1,910
|
Janssen Biotech
|
8
|
Rituxan
|
Rituximab
|
5.6%
($615 to $765)
|
$1,985
|
Genentech, Inc.
|
*Indicates multiple brand and/or generic names for a specific HCPCS
code. **Indicates brand/generic names unavailable. Name reflects the
HCPCS short description.
Medicare Part D
|
|
Brand Name
|
Generic Name
|
Annual Growth Rate (2012-2016)
|
Average Monthly Spending Per Beneficiary in 2016
|
Manufacturers
|
1
|
Renvela
|
Sevelamer Carbonate
|
21.6%
($3 to $6)
|
$630
|
Genzyme
|
2
|
Lantus
|
Insulin Glargine, Hum.Rec.Anlog
|
18.6%
($13 to $25)
|
$209
|
Sanofi-Aventis
|
3
|
Zetia
|
Ezetimibe
|
18.3%
($5 to $9)
|
$181
|
Merck Sharp & D
|
4
|
Enbrel
|
Etanercept
|
18.2%
($498 to $972)
|
$2,741
|
Amgen
|
5
|
Humira Pen
|
Adalimumab
|
18.0%
($1,019 to $1,976)
|
$2,835
|
Abbvie US LLC
|
6
|
Lyrica
|
Pregabalin
|
17.4%
($3 to $6)
|
$205
|
Pfizer US Pharm
|
7
|
Lantus Solostar
|
Insulin Glargine, Hum.Rec.Anlog
|
14.2%
($14 to $25)
|
$196
|
Sanofi-Aventis
|
8
|
Crestor
|
Rosuvastatin Calcium
|
13.2%
($5 to $8)
|
$124
|
Astrazeneca
|
9
|
Januvia
|
Sitagliptin Phosphate
|
12.7%
($7 to $12)
|
$235
|
Merck Sharp & D
|
10
|
Xarelto
|
Rivaroxaban
|
10.6%
($8 to $12)
|
$202
|
Janssen Pharm.
|
11
|
Eliquis
|
Apixaban
|
10.4%
($4 to $6)
|
$194
|
BMS Primarycare
|
Medicaid
|
|
Brand Name
|
Generic Name
|
Annual Growth Rate (2012-2016)
|
Manufacturers
|
1
|
Lantus
|
Insulin Glargine, Hum.Rec.Anlog
|
18.7%
($13 to $25)
|
Sanofi-Aventis
|
2
|
Latuda
|
Lurasidone HCl
|
18.6%
($17 to $33)
|
Sunovion Pharma
|
3
|
Lyrica
|
Pregabalin
|
17.9%
($3 to $6)
|
Pfizer US Pharm
|
4
|
Enbrel
|
Etanercept
|
17.6%
($487 to $933)
|
Amgen
|
5
|
Humira Pen
|
Adalimumab
|
17.5%
($1,007 to $1,919)
|
Abbvie US LLC
|
6
|
Lantus Solostar
|
Insulin Glargine, Hum.Rec.Anlog
|
14.3%
($15 to $25)
|
Sanofi-Aventis
|
7
|
Abilify
|
Aripiprazole
|
11.4%
($21 to $32)
|
Otsuka America
|
8
|
Vyvanse
|
Lisdexamfetamine Dimesylate
|
11.0%
($5 to $8)
|
Shire US Inc.
|
Also,
as part of CMS’s commitment to transparency and data release, CMS today
is updating the Part D Prescriber Public Use File (PUF) with data for
2016. This file includes summarized information on the more than one
million distinct health care providers who prescribed drugs under the
Part D program in 2016. This information enables a range of analyses to
be performed on prescribing trends in Part D. The Part D Prescriber PUF
is available at: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Part-D-Prescriber.html.
In
all of CMS’s efforts, CMS protects the privacy and security of healthcare
data. None of today’s releases include any patient-identifiable data. The
dashboards and a downloadable, machine-readable version of the data
presented in the dashboards can be accessed at: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/index.html.
For
more information, please visit the fact sheet here: https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2018-Fact-sheets-items/2018-05-15.html
#####
Get CMS news at cms.gov/newsroom,
sign up for CMS news via
email and follow CMS on Twitter CMS Administrator @SeemaCMS, @CMSgov,
and @CMSgovPress.
|